ClinicalTrials.gg
CompletedNCT06642987Updated Oct 16, 2024

Study to Evaluate the Bioequivalence of Vonopzan Tablet 20mg(Vonoprazan Fumarate) and Vocinti Tablet 20mg in Healthy Adult Subjects.

A Phase 1 interventional study of Vonoprazan Test 20mg and Vonoprazan Reference 20mg in Gastric Ulcer, sponsored by Hanlim Pharm. Co., Ltd.. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-16.

Sponsored by Hanlim Pharm. Co., Ltd. · Phase 1, Interventional, and Other

From the registry’s dates

  • Registered 11 months after the study started (first participant enrolled Oct 2023, registered Oct 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies testing vonoprazan in Stomach Ulcer — 1 open to participants now, 1 under way, none of them phase 3. vonoprazan · Stomach Ulcer.

Enrollment
8th of 10
30 · median 320
Started
2023
the only one that year
Phase 1
Only one
of the 10
Registered
10th of 10
by date
Lead sponsor
1 of 10
Hanlim Pharm. Co., Ltd.

Among the 10 studies testing vonoprazan in Stomach Ulcer, this one is the 8th largest by enrollment, is the only one that started in 2023, is the only one in phase 1, and was the 10th registered.

Stomach Ulcer

116 studies on the registry are indexed under Stomach Ulcer; 13 are open to participants now.

Browse Stomach Ulcer studies →

Open to participants now

1 of the 10 studies testing vonoprazan in Stomach Ulcer is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About vonoprazan

vonoprazan: first FDA approval 2022 (VOQUEZNA TRIPLE PAK). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 10 Stomach Ulcer studies recruiting now, 6 (60%) set no upper age limit and 3 (30%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 19 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing vonoprazan in Stomach Ulcer, or all of them as a file.
02

Study summary

This clinical trial is an open-label, randomized, fasting, single-dose, two-sequence, two-period, crossover study in healthy subjects to evaluate the bioequivalence of "Vonopzan Tablets 20 mg(Vonoprazan Fumarate)" of Hanlim Pharm.l Co., Ltd. and "Vocinti Tablet 20 mg (Vonoprazan Fumarate)" of Takeda Pharmaceuticals Korea Co., Ltd. in Healthy Adult Subjects.

Read the detailed description

This study is to compare and evaluate the safety and pharmacokinetic characteristics of "Vonopzan Tablets 20 mg(Vonoprazan Fumarate)" of Hanlim Pharm. Co., Ltd. as the test drug and "Vocinti Tablet 20 mg (Vonoprazan Fumarate)" of Takeda Pharmaceuticals Korea Co., Ltd. as the reference drug in healthy adults.

03

Conditions studied

  • Gastric Ulcer

Browse trials for

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Individuals aged 19 years or older at the time of screening
  2. Individuals with no congenital or chronic diseases and no pathological symptoms or findings based on medical examinations (such as EEG, , chest and gastric endoscopy, or gastrointestinal radiology tests, if necessary)
  3. Individuals deemed suitable for the study based on screening tests (e.g., hematology, blood chemistry, serology, and urinalysis) as determined by the principal investigator (or a designated sub-investigator)
  4. Individuals with a (BMI) between 18.0 and 30.0 (BMI calculation: weight (kg) / height (m)²)
  5. Individuals with no history of gastrointestinal surgery that could affect drug absorption.
  6. Individuals who, after receiving a detailed explanation of the clinical trial, fully understand the study, voluntarily decide to participate, and agree in writing to comply with the trial requirements during the study period.

Exclusion criteria

Exclusion Criteria:

  1. Individuals who have taken enzyme-inducing or inhibiting drugs such as barbiturates within 30 days before the start of the study (first dosing day) or medications that might interfere with the study within 10 days before the start of the study (first dosing day)
  2. Individuals who have engaged in excessive alcohol consumption within one month before the start of the study (first dosing day)

    • For men, more than an average of 21 drinks per week
    • For women, more than an average of 14 drinks per week (One drink: 45 mL of distilled spirits or 360 mL of beer or 150 mL of wine)
  3. Individuals who have taken any medication that may interfere with the trial within 10 days prior to the start of the trial (first dose).
  4. Individuals who have participated in clinical trials (including bioequivalence studies) and received drugs within six months before the start of the study (first dosing day)
  5. Individuals who have donated whole blood within 8 weeks or donated blood components within 2 weeks before the start of the study (first dosing day)
  6. Patients with the following conditions:

    • to the components of this drug
    • Currently taking medications containing atazanavir, nelfinavir, or rilpivirine.
  7. Individuals with a history of mental illness
  8. Women who may be pregnant, pregnant women, or brestfeeding women
  9. Individuals who do not agree to use medically recognized dual * methods, excluding hormonal contraceptives, to prevent pregnancy from the first administration of the investigational drug until one week after the last administration of the investigational drug.

    • Medically recognized dual contraception methods: Combining intrauterine devices (IUD, IUS), vasectomy, tubal ligation, and barrier methods of contraception (male condom, female condom, cervical cap, diaphragm, sponge, etc.), or using two or more barrier methods in combination with spermicides.
  10. Individuals deemed unsuitable for this clinical trial for reasons other than the above inclusion/exclusion criteria by the principal investigator (or a designated sub-investigator)
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Vonoprazan Test 20mg

    On the day of the visit, take 1 tablet of the experimental drug orally with 150 mL of water around 8 am.

    Drug: Vonoprazan Test 20mg

  • Active comparator
    Vonoprazan Reference 20mg

    On the day of the visit, take 1 tablet of the comparator drug orally with 150 mL of water around 8 am.

    Drug: Vonoprazan Reference 20mg

Interventions

  • 1 tablets orally once a day

    Also known as: vonoprazan fumarate

  • DrugVonoprazan Reference 20mg

    1 tablets orally once a day

    Also known as: Vonoprazna fumarate

06

What researchers measure

Primary outcomes

  1. Peak Plasma Concentration (Cmax)

    Concentration of vonoprazan in plasma

    Time frame: 36 hours

  2. Area under the plasma concentration versus time curve (AUC)

    Concentration of vonoprazan in plasma

    Time frame: 36 hours

Secondary outcomes

  1. AUCt/AUC∞

    Concentration of vonoprazan in plasma

    Time frame: 36 hours

  2. Half life

    Concentration of vonoprazan in plasma

    Time frame: 36 hours

  3. Tmax

    Concentration of vonoprazan in plasma

    Time frame: 36 hours

  4. AUC ∞

    Concentration of vonoprazan in plasma

    Time frame: 36 hours

07

Study locations

1 site
  • Seok Gyeong Medical Foundation Central Hospital
    Siheung-si, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2023 to primary completion in Nov 2023, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 14, 2024
First posted
Oct 15, 2024
StartActual
Oct 23, 2023
Primary completionActual
Nov 3, 2023
CompletionActual
Feb 23, 2024
Last update
Oct 16, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06642987
Responsible party
Sponsor
First posted
Oct 15, 2024
Start date
Oct 23, 2023
Primary completion
Nov 3, 2023
Completion
Feb 23, 2024
Last update
Oct 16, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vonoprazan

Start the discussion